Key facts
- It has raised $19.7M; the latest was Later Stage VC in Aug 2025.
- Notable investors include MassChallenge, SOSV, SoftBank Investment Advisers, Speedinvest, Octopus Ventures — 26 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Pear Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Pear Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pear Bio
Developer of functional precision medicine-guided therapeutics designed to create personalized cancer treatments through advanced 3D cell culture models. The company's technology uses a proprietary hydrogel that can grow tumors outside the human body and replicate drug resistance to eliminate the trial-and-error process in cancer treatment, enabling oncologists and researchers to select effective treatment options, and advancing personalized medicine and drug discovery.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2015
- Employees
- 28
- Website
- pearbio.com/
- Ownership
- Privately Held (backing)
Pear Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pear Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pear Bio in its N-PORT filings yet. We sweep new filings monthly.